Dear Ms. Walawalkar,


In reference to our EUA Amendment Concurrence letters regarding batches 21003042 (GMP2) and 21003117 (GMP4) dated June 10, 2021 and June 16, 2021, we note the following error:

The first paragraph included the wrong EUA issuance date.

In addition, we have updated the letter to remove the following condition for export from the United States:

Janssen and Emergent agree that the following unredacted documents may be shared, under an appropriate confidentiality agreement, with the regulatory authorities of the countries where the vaccine will be administered— the FDA Form 483 and establishment inspection report from the most recent inspection of the facility, the June 11, 2021 memo Assessment of certain Janssen COVID-19 Vaccine Batches.

This replacement concurrence letter incorporates the correction of the error and removal of the condition for export. The effective date for the concurrence will remain June 10, 2021, the date of the previous EUA Amendment Concurrence letter. Below is the substance of the reissued concurrence letter.


We also refer you to your EUA amendments:

submitted and received on March 5, 2021
submitted and received on March 12, 2021
submitted and received on March 17, 2021
based on our review of the available data and information, we have determined that Janssen’s AD26.COV2.S DS Area 2 batches 21003042 (GMP2) and 21003117 (GMP4) are suitable for use and meet the EUA standard, which is outlined in your Letter of Authorization. Thus, we concur with your request to add these two batches to the EUA.

Because the Bayview facility was not operating in compliance with Current Good Manufacturing Practice requirements at the time these batches were manufactured, through this concurrence letter I am waiving Current Good Manufacturing Practice requirements for these batches, and only these batches, for the duration of this EUA. This concurrence does not add any other batches manufactured at this facility to the EUA at this time and does not add the facility itself to the EUA at this time, nor does it cover vaccine manufactured by combining these batches with different batches of drug substance that are not authorized explicitly under this EUA.

We remind you that any changes that you plan to implement to the description of the product, manufacturing process, facilities, or equipment will need to be submitted as an amendment to the EUA and not implemented without concurrence by the Agency.

If you have any questions, please contact the Regulatory Project Manager, Sudhakar Agnihothram, PhD at 202-870-6949.

Sincerely,

--/S/--

Marion Gruber, PhD
Director
Office of Vaccines and Research
Center for Biologics Evaluation and Research